The lead highlighted in PMID 30894487 as compound 5 has an EC50 of 270 nM against P. falciparum 3D7 and is PubChem CID 134158252. Two sections from the entry are shown below. Similar to the Nuebig CGC-257081 case from above the speed of vendor availability is surprising. In this case a lead published in April was already submitted to PubChem (SID 384293401) by the first vendor at the end of June. It should also be noted that the likelihood of these particular vendors of having licenced the sale of both these compounds from the academic patent assignee could be low. This multi-parasite inhibitor was crystallised with the enzyme from three different species where 6HCU was the Plasmodium target. However, while the ChEMBL assay result (lower section of Fig ) is unfortunately a dead link, a Google search finds an earlier Dundee paper ('Chemical Validation of Methionyl-tRNA Synthetase as a Druggable Target in Leishmania donovani . From this we can establish that, although it was a failed lead DDD806905 (CID 135423081) actually mapped back to WO2000071524 an old SmithKline Beacham compound directed against S aureus methionyl t-RNA synthetase (the minimum parsimonious assumption at this stage is that ChEMBL has redacted the erroneous assay cross reference but the deadlink remains in PubChem. So far so good, but the paper contains the intriguing concluding sentence "We have identified a valuable tool compound, although further optimization is required in terms of both potency and selectivity to obtain a preclinical candidate" (i.e. not compound 5 so the exact results in Table become less relevant). Since there are no published patents from Dundee claiming another series of Lysyl-tRNA synthetase inhibitors we can assume that this clinical candidate is already disclosed in WO2017221002 (but obviously not named as such). While we can only guess the likely candidate, the most potent of the ~90 compounds with EC50 results against Pf33D7 in the 10002 patent was example 93 at 8nM (compared to 320 nM for example 54). Example 93 was successfully extracted by SureChEMBL as CID 132256792. Cross checking against SF revealed a paradox. CID 134158252 (=RN 2170696-76-9) was only indexed against WO2017221002 but SF had not extracted compound 5 from PMID 30894487 from the eight substances they did curate. For the record, this Dundee effort has been declared as the 2018 MMV Project of the year. These two specific ADEV examples give guideline insights as well as demonstrating the utility of the INS360 approach. Importantly, they also show that both public and commercial sources are necessary to provide a complete picture.